A third dose of Covid-19 vaccine can boost a person’s resistance to Omicron variant of coronavirus by as much as 88 per cent, new studies conducted in the UK have found.
A new study has been published in Vaccines that evaluated the effectiveness of Cominarty against documented SARS-CoV-2 infection and symptomatic diseases in the medium to long term.
The Pfizer/BioNTech COVID-19 vaccine is highly effective at preventing infection and symptomatic disease from the Delta variant among 12- to 18-year-olds, research conducted in Israel shows. The findings, published in the New England Journal of Medicine, will likely provide further reassurance the shot is effective against the variant among younger people as the U.S. drug watchdog considers authorising use of the vaccine on children as young as five. The study found the estimated vaccine effectiveness against documented COVID-19 infection in adolescents was 90%, and 93% against symptomatic COVID-19, on days seven to 21 after the second dose.
Corona: Dreyer fordert neuen Warnwert – Impfstoff für 12- bis 17-Jährige ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.